Desh Rakshak Aushdhalaya Ltd.
BSE: DESHRAK · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Desh Rakshak Aushdhalaya Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Desh Rakshak Aushdhalaya Limited is a long-standing Indian manufacturer specialising in Ayurvedic and herbal medicines. The company produces a diverse range of therapeutic products, including tablets, syrups, and oils, marketed under its own brand through a domestic distribution network.
Business Model
The company generates revenue through the manufacturing and sale of traditional herbal formulations across various health segments. It leverages its historical brand equity and Good Manufacturing Practices to distribute products within the Indian domestic market.
- Establishment Year:1901
Growth Outlook
Growth is expected to be driven by the increasing consumer preference for traditional and indigenous healthcare systems in India. The company focuses on maintaining quality standards to sustain its position in the competitive herbal medicine segment.
Key Risks
- Regulatory Compliance. Changes in government regulations regarding Ayurvedic drug manufacturing and quality standards could impact operational costs.
- Market Competition. The company faces intense competition from both established pharmaceutical firms and emerging players in the natural healthcare space.
- Supply Chain Volatility. Dependence on the availability and pricing of raw herbal ingredients may cause fluctuations in production costs.
- Consumer Preference Shifts. A potential shift in consumer behaviour away from traditional remedies towards modern allopathic medicine could affect long-term demand.
Start your research today
Unlock AI insights, financials, peers and live data on Desh Rakshak Aushdhalaya Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹9 Cr
TTM · standalone
NET PROFIT
₹0.73 Cr
TTM · standalone
EPS
₹1.62
TTM · standalone
RETURN ON EQUITY
7.6%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
9.9%
TTM · standalone
P/E
16.6x
Q1 FY26 · standalone
EV/EBITDA
9.8x
Q1 FY26 · standalone
EBITDA MARGIN
21.3%
TTM · standalone
NET PROFIT MARGIN
6.4%
Q3 FY26 · standalone
DEBT TO EQUITY
0.3x
Q2 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Desh Rakshak Aushdhalaya Ltd.DESHRAK | ₹15 Cr | 16.60 | 9.79 | 46.2% | 21.3% | 7.6% | 9.9% | — |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q1 FY26
Financials
Desh Rakshak Aushdhalaya Ltd.
BSE: DESHRAK · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Desh Rakshak Aushdhalaya Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Desh Rakshak Aushdhalaya Limited is a long-standing Indian manufacturer specialising in Ayurvedic and herbal medicines. The company produces a diverse range of therapeutic products, including tablets, syrups, and oils, marketed under its own brand through a domestic distribution network.
Business Model
The company generates revenue through the manufacturing and sale of traditional herbal formulations across various health segments. It leverages its historical brand equity and Good Manufacturing Practices to distribute products within the Indian domestic market.
- Establishment Year:1901
Growth Outlook
Growth is expected to be driven by the increasing consumer preference for traditional and indigenous healthcare systems in India. The company focuses on maintaining quality standards to sustain its position in the competitive herbal medicine segment.
Key Risks
- Regulatory Compliance. Changes in government regulations regarding Ayurvedic drug manufacturing and quality standards could impact operational costs.
- Market Competition. The company faces intense competition from both established pharmaceutical firms and emerging players in the natural healthcare space.
- Supply Chain Volatility. Dependence on the availability and pricing of raw herbal ingredients may cause fluctuations in production costs.
- Consumer Preference Shifts. A potential shift in consumer behaviour away from traditional remedies towards modern allopathic medicine could affect long-term demand.
Start your research today
Unlock AI insights, financials, peers and live data on Desh Rakshak Aushdhalaya Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹9 Cr
TTM · standalone
NET PROFIT
₹0.73 Cr
TTM · standalone
EPS
₹1.62
TTM · standalone
RETURN ON EQUITY
7.6%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
9.9%
TTM · standalone
P/E
16.6x
Q1 FY26 · standalone
EV/EBITDA
9.8x
Q1 FY26 · standalone
EBITDA MARGIN
21.3%
TTM · standalone
NET PROFIT MARGIN
6.4%
Q3 FY26 · standalone
DEBT TO EQUITY
0.3x
Q2 FY26 · standalone
Peers · Pharmaceuticals
As of Q1 FY26